Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Preferred Stock Liabilities (2020)

Ensysce Biosciences (ENSC) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $52935.0 as the latest value for Q4 2020.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $52935.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $52935.0, a N/A change, with the full-year FY2020 number at $52935.0, changed N/A from a year prior.
  • Preferred Stock Liabilities was $52935.0 for Q4 2020 at Ensysce Biosciences, down from $270999.0 in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $4.5 million in Q1 2020 to a low of $52179.0 in Q2 2020.